• Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
  
• Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line).
  
• Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line).
  

PubMed=16309168
Saito H., Tsunenari T., Onuma E., Sato K., Ogata E., Yamada-Okabe H.
Humanized monoclonal antibody against parathyroid hormone-related protein suppresses osteolytic bone metastasis of human breast cancer cells derived from MDA-MB-231.
Anticancer Res. 25:3817-3823(2005)

PubMed=17129361; DOI=10.1111/j.1349-7006.2006.00357.x; PMCID=PMC11159712
Ehata S., Hanyu A., Fujime M., Katsuno Y., Fukunaga E., Goto K., Ishikawa Y., Nomura K., Yokoo H., Shimizu T., Ogata E., Miyazono K., Shimizu K., Imamura T.
Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line.
Cancer Sci. 98:127-133(2007)